Recent Insider Transactions • Aug 23
Lead Independent Director recently sold US$2.8m worth of stock On the 17th of August, Peter Neupert sold around 110k shares on-market at roughly US$25.14 per share. This transaction amounted to 46% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$3.8m more than they bought in the last 12 months. Recent Insider Transactions Derivative • Aug 18
Co-Founder notifies of intention to sell stock Chad Robins intends to sell 321k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of August. If the sale is conducted around the recent share price of US$24.77, it would amount to US$8.0m. For the year to December 2019, Chad's total compensation was 8% salary and 92% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Chad currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$21m more than they bought, via options and on-market transactions in the last 12 months. Breakeven Date Change • Jul 31
Forecast to breakeven in 2028 The 8 analysts covering Adaptive Biotechnologies expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2027. The company is expected to make a profit of US$6.33m in 2028. Average annual earnings growth of 74% is required to achieve expected profit on schedule. Price Target Changed • Jul 30
Price target increased by 13% to US$23.86 Up from US$21.14, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of US$24.18. Stock is up 136% over the past year. The company is forecast to post a net loss per share of US$0.55 next year compared to a net loss per share of US$0.39 last year. お知らせ • Jul 30
Adaptive Biotechnologies Corporation Raises Revenue Guidance for the Full Year 2026 Adaptive Biotechnologies Corporation raised revenue guidance for the full year 2026. For the full year, the company expected revenue for the MRD business to be between $268 million and $278 million, updated from the previous range between $260 million and $270 million. No revenue guidance is provided for the Immune Medicine business. ライブニュース • Jul 30
Adaptive Biotechnologies to Split MRD and Immune Medicine Units After Strong Q2, Raises Outlook Adaptive Biotechnologies reported an exceptional Q2 2026, led by growth and profitability in its Minimal Residual Disease (MRD) business, and announced plans to separate its MRD and Immune Medicine units while raising full year 2026 MRD revenue guidance.
Management’s decision to split the MRD and Immune Medicine businesses signals a clearer operational focus for each segment. The upgraded MRD revenue outlook indicates where the company currently sees the strongest commercial traction.
Adaptive Biotechnologies’ stock trades at $22.56, with a 90-day return of 60.0%, which shows a sharp recent re-rating ahead of or around these business updates.
The combination of a planned business separation and higher MRD revenue guidance offers a cleaner way to assess each segment’s performance. It also introduces execution risk around the split and the future cost structure of both units. Price Target Changed • Jul 22
Price target increased by 8.3% to US$22.29 Up from US$20.57, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of US$21.95. Stock is up 102% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.39 last year. Recent Insider Transactions Derivative • Jul 19
Chief People Officer exercised options and sold US$1.4m worth of stock On the 15th of July, Francis Lo exercised 106k options at a strike price of around US$7.80 and sold these shares for an average price of US$21.48 per share. This trade did not impact their existing holding. Francis currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$17m more than they bought, via options and on-market transactions in the last 12 months. Buy Or Sell Opportunity • Jul 16
Now 22% undervalued Over the last 90 days, the stock has risen 53% to US$22.10. The fair value is estimated to be US$28.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 57% per annum over the same time period. お知らせ • Jul 10
Adaptive Biotechnologies Corporation to Report Q2, 2026 Results on Jul 29, 2026 Adaptive Biotechnologies Corporation announced that they will report Q2, 2026 results After-Market on Jul 29, 2026 ライブニュース • Jul 02
FDA Authorizes clonoSEQ for Key CAR-T Trial Boosting Adaptive Biotechnologies' Clinical Role Imviva Biotech received FDA Investigational Device Exemption authorization to use Adaptive Biotechnologies’ clonoSEQ assay in the TENACITY-01 trial of its CTD402 allogeneic anti-CD7 CAR-T therapy for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and measurable residual disease (MRD)-positive patients.
The IDE approval allows clonoSEQ to be used as a highly sensitive MRD test to screen eligible patients and quantify treatment response, expanding clinical use of Adaptive Biotechnologies’ technology in T-cell malignancies.
Adaptive Biotechnologies’ stock trades at US$22.37, with the share price up 46.9% over the past 30 days.
This IDE authorization places clonoSEQ more squarely into the CAR-T development workflow, which can strengthen Adaptive Biotechnologies’ position in MRD testing for hematologic cancers, though commercial impact will depend on trial progress, eventual outcomes and the pace of broader clinical adoption. ライブニュース • Jun 28
Adaptive Biotechnologies Reveals MRD Split and $300 Million Convertible Notes Offering Adaptive Biotechnologies announced plans to separate its minimal residual disease (MRD) business from its immune medicine operations and launched an upsized US$300 million convertible notes offering to support the transition.
The company’s current share price is US$20.96, with the stock up 63.1% over the past 90 days, placing the announcement in the context of a period of strong recent share price performance.
BTIG highlighted the separation as a way to focus attention on Adaptive Biotechnologies’ core MRD business, while the convertible notes add capital but also introduce future dilution risk once converted.
The combination of a business split and a sizable convertible offering puts the spotlight on how effectively Adaptive Biotechnologies can clarify its business model while balancing the benefits of added capital against the potential impact of future share issuance. Recent Insider Transactions Derivative • Jun 26
Independent Director notifies of intention to sell stock Michelle Griffin intends to sell 52k shares in the next 90 days after lodging an Intent To Sell Form on the 25th of June. If the sale is conducted around the recent share price of US$19.34, it would amount to US$1.0m. Since March 2026, Michelle's direct individual holding has decreased from 15.63k shares to 0. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months. ライブニュース • Jun 18
Adaptive Biotechnologies Stock Reshapes Focus With MRD Separation and $300 Million Convertible Offering Adaptive Biotechnologies plans to separate its profitable Minimal Residual Disease (MRD) diagnostics business from its Immune Medicine unit by the end of 2026, with the MRD arm remaining under company ownership and the Immune Medicine business pursuing options outside the company.
To support the separation and fund growth in MRD, Adaptive Biotechnologies has completed an upsized private offering of US$300 million in 0% convertible senior notes due 2031, above the initial US$250 million target, with an option for an additional US$37.5 million.
The company intends to use the proceeds to repay its OrbiMed Purchase Agreement, repurchase up to US$25 million of common stock, fund capped call transactions to manage potential dilution, and support general corporate purposes and MRD-related growth initiatives.
The combination of a business separation plan and a larger-than-initially-planned convertible notes offering indicates that Adaptive Biotechnologies is reshaping its capital structure and corporate focus around the MRD business while seeking separate paths for its Immune Medicine platform.
Investors may want to monitor how the terms of any eventual Immune Medicine transaction, the execution of debt repayment, and the share repurchase program influence dilution, balance sheet flexibility, and the risk profile of Adaptive Biotechnologies stock. Recent Insider Transactions Derivative • Jun 16
Co-Founder & Chief Scientific Officer notifies of intention to sell stock Harlan Robins intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of June. If the sale is conducted around the recent share price of US$17.46, it would amount to US$1.7m. Since December 2025, Harlan's direct individual holding has increased from 1.23m shares to 1.51m. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months. Buy Or Sell Opportunity • Jun 05
Now 20% undervalued Over the last 90 days, the stock has risen 14% to US$16.90. The fair value is estimated to be US$21.24, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 45% per annum over the same time period. ライブニュース • Jun 05
Adaptive Biotechnologies Showcases clonoSEQ MRD Growth as Revenue Rises 35% and Profitability Targets Near Adaptive Biotechnologies highlighted its clonoSEQ measurable residual disease (MRD) test in 33 presentations at the ASCO and EHA 2026 conferences, reinforcing its use across multiple blood cancers such as multiple myeloma and chronic lymphocytic leukemia.
The company reported that its MRD testing business is profitable and is targeting positive adjusted EBITDA in 2025 and positive free cash flow by the end of 2026.
Q1 2026 total revenue rose 35% year over year, with the MRD segment contributing 95% of revenue and rising 53% compared with Q1 2025, prompting an increase in full-year 2026 MRD revenue guidance.
The combination of strong clinical visibility for clonoSEQ and a business mix heavily skewed to MRD testing provides a clearer view of where most of the company’s current economic engine sits.
Investors may wish to monitor execution against the profitability and cash flow targets, as well as how dependence on a single segment affects risk if MRD growth or adoption patterns change. お知らせ • May 30
Adaptive Biotechnologies Corporation Reports New Data Reinforcing Pivotal Role of clonoSEQ MRD Testing Across Hematology Clinical Practice and Research Adaptive Biotechnologies Corporation announced that its next-generation sequencing (NGS)-based clonoSEQ test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm. Data at ASCO and EHA this year continue to reinforce clonoSEQ’s role in modern hematologic oncology care — as the gold standard for assessing depth of response, longitudinal disease monitoring, and MRD-guided treatment decision-making. Across hematologic malignancies, these studies highlight how MRD measured by clonoSEQ continues to be broadly incorporated into both research and clinical practice: Multiple myeloma: Highly sensitive MRD testing continues to demonstrate depth and durability of response across novel therapies, including follow-up data from the inMMyCAR trial of CAR T-cell therapy and bispecific antibody data from MONUMENTAL-3. In addition, a final analysis from the CEPHEUS trial, the basis for the first-ever FDA approval based on an MRD endpoint, showed higher rates of sustained MRD negativity in patients treated with quadruplet regimen daratumumab plus VRd (bortezomib, lenalidomide, and dexamethasone). Chronic lymphocytic leukemia (CLL): MRD is being incorporated into decisions around therapy duration and discontinuation in studies including BOVen-?MRD400 and venetoSTOP, the latter demonstrating that personalized venetoclax treatment duration based on uMRD5 status leads to durable treatment-free remissions. Acute lymphoblastic leukemia (ALL): In a Phase 2 study evaluating dose-adjusted EPOCH with rituximab and tafasitamab, MRD assessment with clonoSEQ continues to outperform flow cytometry in detecting residual disease and predicting patient outcomes and can be used to assess disease burden in cerebrospinal fluid. Lymphoma: clonoSEQ leverages sensitivity and specificity to support MRD testing in real-world and clinical trial settings across multiple major lymphoma subtypes, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). At EHA this year, new data further expand the evidence base for highly sensitive, next-generation sequencing–based MRD assessment and underscore the increasingly global nature of clonoSEQ’s reach and impact. Across Europe, growing momentum behind MRD-guided care is being driven, in part, by increasing biopharmaceutical industry investment in interventional studies that incorporate MRD into treatment decisions. clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL. clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier. clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). New Risk • May 11
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$50m Forecast net loss in 3 years: US$13m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Significant insider selling over the past 3 months (US$16m sold). Reported Earnings • May 06
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: US$0.13 loss per share (improved from US$0.20 loss in 1Q 2025). Revenue: US$70.9m (up 35% from 1Q 2025). Net loss: US$20.0m (loss narrowed 33% from 1Q 2025). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Breakeven Date Change • May 06
Forecast to breakeven in 2028 The 8 analysts covering Adaptive Biotechnologies expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2027. The company is expected to make a profit of US$1.35m in 2028. Average annual earnings growth of 41% is required to achieve expected profit on schedule. お知らせ • Apr 27
Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 05, 2026 Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 05, 2026. お知らせ • Apr 16
Adaptive Biotechnologies Corporation to Report Q1, 2026 Results on May 05, 2026 Adaptive Biotechnologies Corporation announced that they will report Q1, 2026 results After-Market on May 05, 2026 Recent Insider Transactions Derivative • Feb 28
Co-Founder notifies of intention to sell stock Chad Robins intends to sell 183k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of February. If the sale is conducted around the recent share price of US$16.02, it would amount to US$2.9m. For the year to December 2019, Chad's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Chad's direct individual holding has decreased from 2.96m shares to 1.60m. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Feb 12
Consensus estimates of losses per share improve by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from US$267.4m to US$282.4m. EPS estimate increased from -US$0.572 per share to -US$0.485 per share. Life Sciences industry in the US expected to see average net income growth of 15% next year. Consensus price target up from US$20.14 to US$20.86. Share price fell 5.6% to US$15.54 over the past week. Reported Earnings • Feb 06
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: US$0.39 loss per share (improved from US$1.08 loss in FY 2024). Revenue: US$277.0m (up 55% from FY 2024). Net loss: US$59.5m (loss narrowed 63% from FY 2024). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. お知らせ • Feb 06
Adaptive Biotechnologies Corporation Provides Earnings Guidance for 2026 Adaptive Biotechnologies Corporation provided earnings guidance for 2026. For the period, Adaptive Biotechnologies expects full year revenue for the MRD business to be between $255 millionand $265 million. No revenue guidance is provided for the Immune Medicine business. Recent Insider Transactions Derivative • Feb 03
Co-Founder notifies of intention to sell stock Chad Robins intends to sell 125k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of February. If the sale is conducted around the recent share price of US$18.39, it would amount to US$2.3m. For the year to December 2019, Chad's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Chad's direct individual holding has decreased from 2.96m shares to 1.72m. Company insiders have collectively sold US$13m more than they bought, via options and on-market transactions in the last 12 months. お知らせ • Jan 23
Adaptive Biotechnologies Corporation to Report Q4, 2025 Results on Feb 05, 2026 Adaptive Biotechnologies Corporation announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 05, 2026 Recent Insider Transactions Derivative • Jan 15
Chief People Officer exercised options and sold US$797k worth of stock On the 12th of January, Francis Lo exercised 80k options at a strike price of around US$3.99 and sold these shares for an average price of US$14.01 per share. This trade did not impact their existing holding. Since March 2025, Francis' direct individual holding has decreased from 335.35k shares to 318.48k. Company insiders have collectively sold US$13m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Jan 06
Co-Founder notifies of intention to sell stock Chad Robins intends to sell 125k shares in the next 90 days after lodging an Intent To Sell Form on the 5th of January. If the sale is conducted around the recent share price of US$16.17, it would amount to US$2.0m. For the year to December 2019, Chad's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Chad's direct individual holding has decreased from 2.96m shares to 1.85m. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Dec 19
Chief People Officer exercised options and sold US$893k worth of stock On the 15th of December, Francis Lo exercised 97k options at a strike price of around US$3.99 and sold these shares for an average price of US$13.19 per share. This trade did not impact their existing holding. Since March 2025, Francis has owned 335.35k shares directly. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Dec 14
Independent Director recently sold US$367k worth of stock On the 10th of December, Robert Hershberg sold around 23k shares on-market at roughly US$16.00 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$4.5m more than they bought in the last 12 months. お知らせ • Dec 06
Adaptive Biotechnologies Corporation Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting Adaptive Biotechnologies Corporation announced growing interventional use of its clonoSEQ test among the 90 abstracts featuring clonoSEQ data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6-9, 2025, in Orlando. Notably, 17 abstracts utilizing Adaptive's clonoSEQ test exemplify how next-generation sequencing-based measurable residual disease (MRD) status is guiding clinical actions to improve blood cancer patient care. The presentations below show how investigators are applying clonoSEQ MRD results to tailor treatment intensity or duration with greater precision. Multiple Myeloma (MM). A total of 32 abstracts will be presented (31 MM, one smoldering MM), with a focus on MRD assessment of treatment response, real-world data demonstrating the link between MRD status and clinical outcomes, and several studies describing how clonoSEQ MRD Results are being used to guide treatment decisions. A presentation focused on MRD dynamics in the phase III AURIGA study of 200 newly diagnosed MM patients demonstrated that deep MRD responses and sustained MRD negativity correlated with improved progression free survival. The study shows that use of intensified maintenance in MRD-positive patients post-transplant doubled MRD negativity rates (oral presentation, abstract 97). Non-Hodgkin Lymphoma (NHL). Fifteen abstracts in NHL will be presented, focusing on use of MRD to better understand depth of response and to guide therapy. New Risk • Dec 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$33m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Recent Insider Transactions Derivative • Nov 20
Insider notifies of intention to sell stock Sharon Benzeno intends to sell 96k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of November. If the sale is conducted around the recent share price of US$13.75, it would amount to US$1.3m. Since March 2025, Sharon's direct individual holding has decreased from 392.72k shares to 95.93k. Company insiders have collectively sold US$5.6m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Nov 12
Consensus estimates of losses per share improve by 27% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$239.4m to US$256.0m. EPS estimate increased from -US$0.678 per share to -US$0.493 per share. Life Sciences industry in the US expected to see average net income growth of 16% next year. Consensus price target up from US$17.14 to US$18.57. Share price fell 18% to US$14.50 over the past week. Price Target Changed • Nov 11
Price target increased by 8.3% to US$18.57 Up from US$17.14, the current price target is an average from 7 analysts. New target price is 28% above last closing price of US$14.53. Stock is up 145% over the past year. The company is forecast to post a net loss per share of US$0.49 next year compared to a net loss per share of US$1.08 last year. Recent Insider Transactions Derivative • Nov 11
Co-Founder notifies of intention to sell stock Chad Robins intends to sell 86k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of November. If the sale is conducted around the recent share price of US$14.71, it would amount to US$1.3m. For the year to December 2018, Chad's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Chad's direct individual holding has decreased from 2.96m shares to 2.10m. Company insiders have collectively sold US$5.6m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Nov 06
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: US$0.063 (up from US$0.22 loss in 3Q 2024). Revenue: US$94.0m (up 102% from 3Q 2024). Net income: US$9.55m (up US$41.6m from 3Q 2024). Profit margin: 10% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 45%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year and the company’s share price has also increased by 20% per year. お知らせ • Nov 06
Adaptive Biotechnologies Corporation Updates Earnings Guidance for the Full Year 2025 Adaptive Biotechnologies Corporation updates earnings guidance for the full year 2025. The company expected full year revenue for the MRD business to be between $202 million and $207 million, updated from the previous range between $190 million and $200 million. No revenue guidance is provided for the Immune Medicine business. お知らせ • Oct 16
Adaptive Biotechnologies Corporation to Report Q3, 2025 Results on Nov 05, 2025 Adaptive Biotechnologies Corporation announced that they will report Q3, 2025 results After-Market on Nov 05, 2025 Major Estimate Revision • Aug 12
Consensus estimates of losses per share improve by 10% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$218.3m to US$227.7m. EPS estimate increased from -US$0.846 per share to -US$0.761 per share. Life Sciences industry in the US expected to see average net income growth of 15% next year. Consensus price target up from US$12.14 to US$14.00. Share price rose 15% to US$12.66 over the past week. Price Target Changed • Aug 06
Price target increased by 7.2% to US$12.71 Up from US$11.86, the current price target is an average from 7 analysts. New target price is 8.8% above last closing price of US$11.69. Stock is up 179% over the past year. The company is forecast to post a net loss per share of US$0.76 next year compared to a net loss per share of US$1.08 last year. お知らせ • Aug 06
Adaptive Biotechnologies Corporation Updates Financial Guidance for the Full Year 2025 Adaptive Biotechnologies Corporation updated financial guidance for the full year 2025. For the year, the company expects full year revenue for the MRD business to be between $190 million and $200 million, updated from the previous range between $180 million and $190 million. No revenue guidance is provided for the Immune Medicine busine. お知らせ • Jul 16
Adaptive Biotechnologies Corporation to Report Q2, 2025 Results on Aug 05, 2025 Adaptive Biotechnologies Corporation announced that they will report Q2, 2025 results After-Market on Aug 05, 2025 お知らせ • May 30
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers Adaptive Biotechnologies Corporation announced that its next-generation sequencing (NGS)-based clonoSEQ®? test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. Data to be presented at ASCO: Presentation Type and Number Title Presentation Timing B-Cell Acute Lymphoblastic Leukemia. Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, Sunday, June 1, 6540 cyclophosphamide, and doxorubicin (DA-EPOCH) + rituximab (R) + tafasitamab (tafa) for adults 9 a.m.-12 p.m. CDT with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL). Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute Sunday, June 1, 6543 lymphoblastic leukemia 9 a.m.-12p.m. CDT Multiple Myeloma: Multiple Myeloma: Primary endpoints of Tuesday, June 3, 7501 lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple. Price Target Changed • May 04
Price target increased by 8.8% to US$10.57 Up from US$9.71, the current price target is an average from 7 analysts. New target price is 7.4% above last closing price of US$9.84. Stock is up 227% over the past year. The company is forecast to post a net loss per share of US$0.83 next year compared to a net loss per share of US$1.08 last year. Reported Earnings • May 02
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: US$0.20 loss per share (improved from US$0.33 loss in 1Q 2024). Revenue: US$52.4m (up 25% from 1Q 2024). Net loss: US$29.9m (loss narrowed 37% from 1Q 2024). Revenue exceeded analyst estimates by 24%. Earnings per share (EPS) also surpassed analyst estimates by 33%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 6% per year. お知らせ • May 02
Adaptive Biotechnologies Corporation Revises Earnings Guidance for 2025 Adaptive Biotechnologies Corporation revised earnings guidance for 2025. For the period, the company expects full year revenue for the MRD business to be between $180 million and $190 million, updated from the previous range between $175 million and $185 million. No revenue guidance is provided for the Immune Medicine business. お知らせ • Apr 30
Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2025 Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2025. Location: entirely via the internet, United States お知らせ • Apr 11
Adaptive Biotechnologies Corporation to Report Q1, 2025 Results on May 01, 2025 Adaptive Biotechnologies Corporation announced that they will report Q1, 2025 results After-Market on May 01, 2025 Recent Insider Transactions Derivative • Mar 11
Independent Director notifies of intention to sell stock Michelle Griffin intends to sell 16k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of March. If the sale is conducted around the recent share price of US$7.94, it would amount to US$124k. Since June 2024, Michelle's direct individual holding has decreased from 51.96k shares to 51.69k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months. お知らせ • Mar 11
Adaptive Biotechnologies Corporation Launches Assay Enhancements to Increase clonoSEQ Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma Adaptive Biotechnologies Corporation announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity. The assay leverages the same powerful technology as prior versions, detecting MRD by reading the full immune receptor sequence of the malignant B cells rather than relying on individual point mutations. Maintaining this proprietary approach enables improvements in sensitivity while preserving the exquisite specificity that minimizes risk of overtreatment due to false positives. The enhanced assay was previously made available for research use in November 2023 and is already being incorporated into both biopharma-sponsored and investigator-initiated prospective trials. Data generated using this assay and presented at ASH 2024 by Bond and colleagues demonstrated that in patients for which MRD was assessed by clonoSEQ, MRD negativity post-cycle six was highly prognostic of progression-free survival. clonoSEQ is the first and only DLBCL MRD test available for clinical use. Having secured Medicare coverage for clonoSEQ in DLBCL in July of 2022, Adaptive has since provided MRD testing for more than 2,800 DLBCL patients and was used to manage and inform patient care by over 640 providers in 2024 alone. The New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) recently approved the enhanced version of the clonoSEQ ctDNA assay for the detection and monitoring of MRD in patients with DLBCL. This comes on the heels of the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas, which included language recommending ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of first-line treatment. Because DLBCL outcomes can vary widely following frontline treatment, the ability of MRD results to accurately risk stratify patients in this setting is critical, as an MRD test can help clinicians differentiate a likely cure from an impending relapse. As the number of clinical trials in DLBCL exploring novel MRD-directed treatment consolidation strategies to reduce relapse rates grows, the role for clonoSEQ as a highly sensitive and specific ctDNA-based test will continue to expand. Recent Insider Transactions • Mar 07
Co-Founder recently sold US$1.6m worth of stock On the 6th of March, Chad Robins sold around 220k shares on-market at roughly US$7.29 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Chad's only on-market trade for the last 12 months. 
